HSBC Holdings
DYN icon

HSBC Holdings’s Dyne Therapeutics DYN Stock Holding History

HSBC Holdings’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,330
Closed -$157K – 2800
2025
Q2 		$157K Sell
16,330
-12,066
-42% -$133K ﹤0.01% 2752
2025
Q1 		$286K Buy
28,396
+15,042
+113% +$215K ﹤0.01% 2410
2024
Q4 		$316K Buy
13,354
+4,178
+46% +$124K ﹤0.01% 2464
2024
Q3 		$326K Buy
+9,176
New +$365K ﹤0.01% 2281
2023
Q1 		– Sell
-10,649
Closed -$119K – 2771
2022
Q4 		$119K Sell
10,649
-356
-3% -$4.12K ﹤0.01% 2881
2022
Q3 		$143K Hold
11,005
– – ﹤0.01% 2701
2022
Q2 		$77K Hold
11,005
– – ﹤0.01% 3083
2022
Q1 		$105K Hold
11,005
– – ﹤0.01% 3115
2021
Q4 		$130K Buy
+11,005
New +$155K ﹤0.01% 3110

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HSBC Holdings's DYN Position: Q3 2025 in Review

HSBC Holdings sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 16,330 shares — an estimated $157K sold.

HSBC Holdings first reported a position in DYN in Q4 2021 and held it in 9 quarters. The position peaked at $326K in Q3 2024. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • HSBC Holdings reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 16,330 Dyne Therapeutics shares in Q3 2025, an estimated $157K.
  • HSBC Holdings first reported a position in Dyne Therapeutics in Q4 2021 and held it in 9 quarters.
  • HSBC Holdings's Dyne Therapeutics position peaked at $326K in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.